Best in Biotech 28 Oct 2025 The 11 most advanced microbiome players aiming for the gut Take a look at 11 of the top biotech companies working on the development of gut microbiome therapies to treat a range of diseases. October 28, 2025 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2025 The ESMO 2025 digest: Is oncology in good shape? The 2025 edition of the European Society for Medical Oncology (ESMO) was held this week in Berlin, delve into its key highlights. October 24, 2025 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 22 Oct 2025 PCSK9’s second act: From antibodies to gene editing With Eli Lilly’s recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents. October 22, 2025 - 6 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 17 Oct 2025 NLS Days: How do things look for biotech in Sweden? As Labiotech attented the NLS Days this week, it was the occasion to learn more about the biotech industry in Sweden. October 17, 2025 - 11 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 9 Oct 2025 Are European biotech VCs under pressure to scale? Time to get pragmatic As Asabys Partners has rolled Aliath Bioventures into its platform, it’s worth asking if European biotech VCs are under pressure to scale. October 9, 2025 - 5 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 7 Oct 2025 AKIGAI takes EGFR inhibitors beyond cancer to treat neuropathic pain Discover how AKIGAI’s EGFR inhibitors may redefine neuropathic pain therapy and offer hope for complex regional pain syndrome (CRPS). October 7, 2025 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 1 Oct 2025 Asthma study suggests lung scarring may be reversible Find out about this new study that suggest that the lung scarring that severe asthma can cause could be reversible. October 1, 2025 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 Sep 2025 CRISPR technology’s next wave: Ten companies to watch in 2025 Driven by CASGEVY’s success, the CRISPR field is experiencing substantial growth with a new wave of companies. September 30, 2025 - 15 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 24 Sep 2025 Eli Lilly’s strategy in motion: Beyond diabetes and obesity Delve into a biopharma giant’s strategy, Eli Lilly. This past year, the company secured regulatory milestones and strategic deals. September 24, 2025 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 23 Sep 2025 Navigating German biotech: 14 key players to know The German biotech ecosystem is well established despite the challenges it is facing. Discover thirteen key Germany-based biotech companies. September 23, 2025 - 16 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Interview 15 Sep 2025 Tapping into the regulatory goldmine: Interview with Ruxandra Teslo The FDA is sitting on a data goldmine: CTds. These documents could help biotech navigate regulations, but how to make them public? September 15, 2025 - 9 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2025 With Lykos CRL now public, FDA opens new era of accountability As the release of a CRL declining Lykos’ therapy generates a strong reaction from MAPS, delve into what this new transparency could change. September 8, 2025 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email